SYNTHROID (levothyroxine sodium) by AbbVie is synthesis. First approved in 2002.
Drug data last refreshed 3d ago
SYNTHROID (levothyroxine sodium) is an oral tablet thyroid hormone replacement therapy manufactured by AbbVie, approved by the FDA on July 24, 2002. It is indicated for treatment of hypothyroidism across multiple etiologies including primary, secondary (pituitary), and tertiary (hypothalamic) forms, as well as adjunctive therapy in thyroid cancer management. The drug works by replacing or supplementing endogenous thyroid hormones; levothyroxine (T4) is peripherally converted to the active form triiodothyronine (T3), which binds to thyroid receptors in cell nuclei to modulate gene transcription and protein synthesis. SYNTHROID remains the standard-of-care thyroid replacement therapy and is among the most prescribed medications in the United States.
synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
Worked on SYNTHROID at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
$355M Medicare spend — this is a commercially significant brand
SYNTHROID supports careers in brand management, medical science liaison (MSL) roles, and field sales teams focused on maintaining market share against generic competition and alternative branded formulations. Success in this role requires deep knowledge of thyroid physiology, familiarity with endocrinology prescribing patterns, and ability to articulate differentiation in a crowded generic marketplace. Currently, zero open positions are linked to SYNTHROID in the available data, reflecting the mature and stable nature of the product portfolio.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo